Morgan Stanley says Nuix sell-off was “too severe”
Morgan Stanley says the 32 per cent fall in Nuix’s share price on Friday was “too severe”, with the broker remaining positive on the ASX-newcomer’s outlook despite its first half result disappointing expectations.
The broker held steady with its overweight rating and $11.00 price target, even after the company’s shares fell to $6.06.
”At first look [the first half] results are a miss versus expectations and thus the risk profile surrounding full-year earnings delivery has increased,” said Morgan Stanley analyst Andrew McLeod.
“But, importantly, the company states the new business pipeline in the second half is strong and visibility provides confidence to reiterate all full-year FY21 numbers.”
Nuix blamed unexpected delays in contracts from December to January as a key reason behind the results miss while a strong Australian dollar also represented an unexpected headwind. Despite this, the company reiterated its guidance for full year revenue to be $194 million, annual contract value to be $200 million and EBITDA to be $64 million.
“We think the negative reaction is too severe,” said Mr McLeod.
“We remain confident in the opportunity from expansion into new verticals; a shift to software-as-a-service, and accretive mergers & acquisitions.”
Morgan Stanley is forecasting Nuix will enter the S&P/ASX 200 Index at the March quarterly rebalance. It said the stock only just missed out on inclusion in January when Pointsbet replaced Saracen Mineral Holdings following the gold miner’s merger with Northern Star Resources.
- Forums
- ASX - By Stock
- Nuix inclusion in ASSX-200? A ray of hope?
NXL
nuix limited
Add to My Watchlist
0.46%
!
$2.18

Morgan Stanley says Nuix sell-off was “too severe”Morgan Stanley...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.18 |
Change
-0.010(0.46%) |
Mkt cap ! $720.9M |
Open | High | Low | Value | Volume |
$2.25 | $2.25 | $2.14 | $941.6K | 432.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3005 | $2.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.20 | 3005 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3005 | 2.170 |
1 | 3005 | 2.160 |
6 | 38007 | 2.150 |
2 | 1200 | 2.140 |
1 | 1103 | 2.130 |
Price($) | Vol. | No. |
---|---|---|
2.200 | 3005 | 1 |
2.210 | 3005 | 1 |
2.220 | 3005 | 1 |
2.230 | 3500 | 1 |
2.250 | 10216 | 2 |
Last trade - 16.10pm 01/07/2025 (20 minute delay) ? |
Featured News
NXL (ASX) Chart |
The Watchlist
AFT
AFT Pharmaceuticals Limited
Dr. Hartley Atkinson, MD
Dr. Hartley Atkinson
MD
Previous Video
Next Video
SPONSORED BY The Market Online